Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | IDE | P14735 | 1/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 5/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22783664 | 0.81 | JAK2 (0.61) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL9786590 | 0.78 | L3MBTL1 (0.48) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL2894307 | 0.76 | JAK2 (0.57) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL9786577 | 0.75 | L3MBTL1 (0.46) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL5419895 | 0.75 | GAA (0.46) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL7339717 | 0.73 | PDE4A (0.66) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL10807868 | 0.72 | NSD2 (0.43) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL3017686 | 0.72 | CYP1A2 (0.58) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL10817190 | 0.70 | TDP1 (0.54) | GAANSD2ABL1IDERIN1 | |
| SCHEMBL9786600 | 0.70 | NSD2 (0.42) | GAANSD2ABL1IDERIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0169164-B1 | IMIDAZOLONECARBONYLARYLIMIDAZOLES; METHOD OF MANUFACTURE, METHOD OF USE AND COMPOSITIONS USEFUL THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-31 | — | — | EP | claimed |
| US-4709043-A | Process for the preparation of imidazolonecarbonylarylimidazoles | SCHERING A.G. (DE) | 1987-11-24 | — | — | US | claimed |
| EP-0169164-A1 | Imidazolonecarbonylarylimidazoles; method of manufacture, method of use and compositions useful thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-01-22 | — | — | EP | claimed |
| CN-116283920-B | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2024-04-16 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| CN-101790313-A | Compound (I) | SMITHKLINE BEECHAM CORP | 2010-07-28 | — | — | CN | disclosed |
| EP-0169164-B1 | IMIDAZOLONECARBONYLARYLIMIDAZOLES; METHOD OF MANUFACTURE, METHOD OF USE AND COMPOSITIONS USEFUL THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-31 | — | — | EP | disclosed |
| US-4709043-A | Process for the preparation of imidazolonecarbonylarylimidazoles | SCHERING A.G. (DE) | 1987-11-24 | — | — | US | disclosed |
| EP-0169164-A1 | Imidazolonecarbonylarylimidazoles; method of manufacture, method of use and compositions useful thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-01-22 | — | — | EP | disclosed |
| US-4556665-A | Cardiotonic 1,3-dihydro-4-[[(imidazol-1-yl)aryl]carbonyl]imidazol-2-ones | SCHERING A.G. (DE) | 1985-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | GAA 177/4885NSD2 587/4885ABL1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.